IP Library › Granted Patent US 12,281,175
Granted Patent B2
US 12,281,175 · App. 17/011,849 · Granted Apr 22, 2025

Binding molecules for BCMA and CD3

Inventors: Peter Kufer (Munich, DE); Tobias Raum (Munich, DE); Patrick Hoffmann (Munich, DE); Roman Kischel (Munich, DE); Ralf Lutterbuese (Munich, DE); Doris Rau (Munich, DE); Paul Adam (Munich, DE); Eric Borges (Munich, DE); Barbara Hebeis (Munich, DE); Susanne Hipp (Munich, DE)
Assignees: Amgen Inc.; Amgen Research (Munich) GmbH
C07K16/468A61K39/0005C07K14/70578C07K16/2809C07K16/2875C07K16/2878A61K2039/505A61K2039/575C07K2317/31C07K2317/33C07K2317/34C07K2317/56C07K2317/565C07K2317/622C07K2317/73C07K2317/92C07K2317/94C07K2319/00C07K2319/21C07K2319/30C07K2319/31C07K2319/43
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,175
App. No.
17/011,849
Granted
Apr 22, 2025
Kind
B2
Abstract

The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.

Claims (25)

1. A method of inducing cytotoxicity in a cell expressing human B cell maturation antigen (BCMA) comprising:

contacting the cell with a bispecific binding molecule comprising:

a first binding domain that binds to human CD3; and

a second binding domain that binds to human BCMA,

wherein the binding molecule has an EC 50 of ≤5,000 pg/ml and greater than 5 pg/ml, when the EC 50 is measured in a cell-based cytotoxicity assay comprising combining BCMA-positive human multiple myeloma L363 cells and unstimulated human peripheral blood mononuclear cells (PBMCs) at a ratio of 1:10, incubating the combined L363 cells and PBMCs with the bispecific binding molecule, and performing a propidium iodide FACS assay after 48 hours of incubation.

2. The method of claim 1 , wherein the bispecific binding molecule is a human or humanized antibody.

3. The method of claim 1 , wherein the bispecific binding molecule further comprises an IgG framework.

4. The method of claim 1 , wherein the bispecific binding molecule further comprises an Fc constant domain.

5. The method of claim 1 , wherein the first binding domain that binds to human CD3 is linked to the second binding domain that binds to human BCMA via at least one disulfide bond.

6. The method of claim 1 , wherein the second binding domain comprises a variable heavy chain and a variable light chain.

7. The method of claim 1 , wherein the human CD3 is human CD3 epsilon.

8. The method of claim 1 , wherein the contacting comprises administering the bispecific binding molecule to a human subject in need thereof.

9. The method of claim 8 , wherein the administering to the subject comprises infusion or injection.

10. The method of claim 8 , wherein the administering to the subject comprises intravenous or subcutaneous administration.

11. A method of treating a multiple myeloma subject comprising:

administering to a human subject diagnosed as having multiple myeloma a bispecific binding molecule comprising:

a first binding domain that binds to human CD3; and

a second binding domain that binds to human BCMA,

thereby treating the multiple myeloma,

wherein the binding molecule has an EC 50 of ≤5,000 pg/ml and greater than 5 pg/ml, when the EC 50 is measured in a cell-based cytotoxicity assay comprising combining BCMA-positive human multiple myeloma L363 cells and unstimulated human peripheral blood mononuclear cells (PBMCs) at a ratio of 1:10, incubating the combined L363 cells and PBMCs with the bispecific binding molecule, and performing a propidium iodide FACS assay after 48 hours of incubation.

12. The method of claim 11 , wherein the administering to the human subject comprises infusion or injection.

13. The method of claim 11 , wherein the administering to the human subject comprises intravenous or subcutaneous administration.

14. The method of claim 11 , further comprising administering an additional anti-cancer therapy to the human subject.

15. The method of claim 11 , comprising repeating the administering until a symptom of the multiple myeloma is improved.

16. The method of claim 8 , wherein the human subject is diagnosed as having multiple myeloma.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2021
From: KUFER, PETER; RAUM, TOBIAS; HOFFMANN, PATRICK; KISCHEL, ROMAN; LUTTERBUESE, RALF; RAU, DORIS; ADAM, PAUL; BORGES, ERIC; HEBEIS, BARBARA; HIPP, SUSANNE
To: AMGEN RESEARCH (MUNICH) GMBH; BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 055905/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2021
From: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
To: AMGEN INC.
Reel/Frame 055907/0080 →
Continuity (9)
Continuation 14358511
Provisional Application 61651486 · May 24, 2012
Provisional Application 61651474 · May 24, 2012
Provisional Application 61560183 · Nov 15, 2011
Provisional Application 61560162 · Nov 15, 2011
Provisional Application 61560149 · Nov 15, 2011
Provisional Application 61560144 · Nov 15, 2011
Provisional Application 61560178 · Nov 15, 2011
Related Publication 20220064336A1 · Mar 3, 2022
References Cited (400)
US 3691016A · Patel et al. · 1972 [cited by applicant]
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 3969287A · Jaworek et al. · 1976 [cited by applicant]
US 4179337A · Davis et al. · 1979 [cited by applicant]
US 4195128A · Hildebrand et al. · 1980 [cited by applicant]
US 4229537A · Hodgins et al. · 1980 [cited by applicant]
US 4247642A · Hirohara et al. · 1981 [cited by applicant]
US 4263428A · Apple et al. · 1981 [cited by applicant]
US 4281061A · Zuk et al. · 1981 [cited by applicant]
US 4301144A · Iwashita et al. · 1981 [cited by applicant]
US 4330440A · Ayers et al. · 1982 [cited by applicant]
US 4439196A · Higuchi · 1984 [cited by applicant]
US 4447224A · DeCant, Jr. et al. · 1984 [cited by applicant]
US 4447233A · Mayfield · 1984 [cited by applicant]
US 4475916A · Himmelstein · 1984 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4486194A · Ferrara · 1984 [cited by applicant]
US 4487603A · Harris · 1984 [cited by applicant]
US 4496689A · Mitra · 1985 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 4596556A · Morrow et al. · 1986 [cited by applicant]
US 4615885A · Nakagame et al. · 1986 [cited by applicant]
US 4619794A · Hauser · 1986 [cited by applicant]
US 4640835A · Shimizu et al. · 1987 [cited by applicant]
US 4670417A · Iwasaki et al. · 1987 [cited by applicant]
US 4694778A · Learn et al. · 1987 [cited by applicant]
US 4751180A · Cousens et al. · 1988 [cited by applicant]
US 4767628A · Hutchinson · 1988 [cited by applicant]
US 4790824A · Morrow et al. · 1988 [cited by applicant]
US 4791192A · Nakagawa et al. · 1988 [cited by applicant]
US 4816397A · Boss et al. · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4879231A · Stroman et al. · 1989 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 4941880A · Burns · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5064413A · McKinnon et al. · 1991 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5260203A · Ladner et al. · 1993 [cited by applicant]
US 5292658A · Cormier et al. · 1994 [cited by applicant]
US 5312335A · McKinnon et al. · 1994 [cited by applicant]
US 5383851A · McKinnon et al. · 1995 [cited by applicant]
US 5399163A · Peterson et al. · 1995 [cited by applicant]
US 5418155A · Cormier et al. · 1995 [cited by applicant]
US 5470582A · Supersaxo et al. · 1995 [cited by applicant]
US 5476786A · Huston · 1995 [cited by applicant]
US 5476996A · Wilson et al. · 1995 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5565332A · Hoogenboom et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5585089A · Queen et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5612205A · Kay et al. · 1997 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5643763A · Dunn et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5683888A · Campbell · 1997 [cited by applicant]
US 5693761A · Queen et al. · 1997 [cited by applicant]
US 5693762A · Queen et al. · 1997 [cited by applicant]
US 5698767A · Wilson et al. · 1997 [cited by applicant]
US 5721367A · Kay et al. · 1998 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5741668A · Ward et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5777079A · Tsien et al. · 1998 [cited by applicant]
US 5789215A · Berns et al. · 1998 [cited by applicant]
US 5789650A · Lonberg et al. · 1998 [cited by applicant]
US 5804387A · Cormack et al. · 1998 [cited by applicant]
US 5814318A · Lonberg et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5859205A · Adair et al. · 1999 [cited by applicant]
US 5874299A · Lonberg et al. · 1999 [cited by applicant]
US 5874304A · Zolotukhin et al. · 1999 [cited by applicant]
US 5876995A · Bryan · 1999 [cited by applicant]
US 5877397A · Lonberg et al. · 1999 [cited by applicant]
US 5925558A · Tsien et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 5958765A · Brams et al. · 1999 [cited by applicant]
US 5976796A · Szalay et al. · 1999 [cited by applicant]
US 5977322A · Marks et al. · 1999 [cited by applicant]
US 5981175A · Loring et al. · 1999 [cited by applicant]
US 6023010A · Krimpenfort et al. · 2000 [cited by applicant]
US 6037453A · Jardieu et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6114598A · Kucherlapati et al. · 2000 [cited by applicant]
US 6146826A · Chalfie et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6162963A · Kucherlapati et al. · 2000 [cited by applicant]
US 6214388B1 · Benz et al. · 2001 [cited by applicant]
US 6255458B1 · Lonberg et al. · 2001 [cited by applicant]
US 6300064B1 · Knappik et al. · 2001 [cited by applicant]
US 6407213B1 · Carter et al. · 2002 [cited by applicant]
US 6458547B1 · Bryan et al. · 2002 [cited by applicant]
US 6673986B1 · Kucherlapati et al. · 2004 [cited by applicant]
US 6774106B2 · Theill et al. · 2004 [cited by applicant]
US 6833268B1 · Green et al. · 2004 [cited by applicant]
US 7112324B1 · Dorken et al. · 2006 [cited by applicant]
US 7125689B2 · Carr et al. · 2006 [cited by applicant]
US 7435871B2 · Green et al. · 2008 [cited by applicant]
US 7728114B2 · Mach et al. · 2010 [cited by applicant]
US 8076459B2 · Hofmeister et al. · 2011 [cited by applicant]
US 8105603B2 · Kelley et al. · 2012 [cited by applicant]
US 8236308B2 · Kischel et al. · 2012 [cited by applicant]
US 8784821B1 · Kufer et al. · 2014 [cited by applicant]
US 8790645B2 · Kufer et al. · 2014 [cited by applicant]
US 9034324B2 · Kalled et al. · 2015 [cited by applicant]
US 9150664B2 · Kufer · 2015 [cited by examiner]
US 9260522B2 · Kufer et al. · 2016 [cited by applicant]
US 9340621B2 · Kufer · 2016 [cited by examiner]
US 9410994B2 · Heo et al. · 2016 [cited by applicant]
US 9598500B2 · Kufer · 2017 [cited by examiner]
US 9725506B2 · Dillon et al. · 2017 [cited by applicant]
US 9850320B2 · Bernett et al. · 2017 [cited by applicant]
US 9856327B2 · Bernett et al. · 2018 [cited by applicant]
US 10059766B2 · Xiao et al. · 2018 [cited by applicant]
US 10294300B2 · Raum et al. · 2019 [cited by applicant]
US 10301391B2 · Raum et al. · 2019 [cited by applicant]
US 10519241B2 · Raum et al. · 2019 [cited by applicant]
US 10683351B2 · Raum et al. · 2020 [cited by applicant]
US 10752694B2 · Kufer · 2020 [cited by examiner]
US 10766969B2 · Kufer · 2020 [cited by examiner]
US 10781264B2 · Raum et al. · 2020 [cited by applicant]
US 10851170B2 · Raum et al. · 2020 [cited by applicant]
US 10981998B2 · Kufer et al. · 2021 [cited by applicant]
US 11434302B2 · Raum et al. · 2022 [cited by applicant]
US 11447567B2 · Raum et al. · 2022 [cited by applicant]
US 11472886B2 · Kufer et al. · 2022 [cited by applicant]
US 11591396B2 · Raum et al. · 2023 [cited by applicant]
US 20020173629A1 · Jakobovits et al. · 2002 [cited by applicant]
US 20030070185A1 · Jakobovits et al. · 2003 [cited by applicant]
US 20030078385A1 · Arathoon et al. · 2003 [cited by applicant]
US 20030091561A1 · van de Winkel et al. · 2003 [cited by applicant]
US 20040052783A1 · Weiner et al. · 2004 [cited by applicant]
US 20050076395A1 · Kucherlapati et al. · 2005 [cited by applicant]
US 20050249723A1 · Lazar et al. · 2005 [cited by applicant]
US 20050265993A1 · Mach et al. · 2005 [cited by applicant]
US 20060099582A1 · Papadopoulos et al. · 2006 [cited by applicant]
US 20060177896A1 · Mach et al. · 2006 [cited by applicant]
US 20060193852A1 · Dorken et al. · 2006 [cited by applicant]
US 20070212733A1 · Martin · 2007 [cited by applicant]
US 20070264687A1 · Chou et al. · 2007 [cited by applicant]
US 20080260738A1 · Moore et al. · 2008 [cited by applicant]
US 20080299129A1 · Lewis et al. · 2008 [cited by applicant]
US 20080311078A1 · Gokarn et al. · 2008 [cited by applicant]
US 20090252729A1 · Farrington et al. · 2009 [cited by applicant]
US 20090304696A1 · Lawson et al. · 2009 [cited by applicant]
US 20090325196A1 · Dillon et al. · 2009 [cited by applicant]
US 20100150918A1 · Kufer et al. · 2010 [cited by applicant]
US 20100183615A1 · Kufer et al. · 2010 [cited by applicant]
US 20110123532A1 · Gurney et al. · 2011 [cited by applicant]
US 20110212094A1 · Ghayur et al. · 2011 [cited by applicant]
US 20110274685A1 · Keler et al. · 2011 [cited by applicant]
US 20110293579A1 · Nielsen et al. · 2011 [cited by applicant]
US 20110293619A1 · Kufer et al. · 2011 [cited by applicant]
US 20120034228A1 · Kufer et al. · 2012 [cited by applicant]
US 20120244162A1 · Kufer et al. · 2012 [cited by applicant]
US 20130078249A1 · Ast et al. · 2013 [cited by applicant]
US 20130078250A1 · Ast et al. · 2013 [cited by applicant]
US 20130129723A1 · Blankenship et al. · 2013 [cited by applicant]
US 20130273055A1 · Borges et al. · 2013 [cited by applicant]
US 20140112914A1 · Nezu et al. · 2014 [cited by applicant]
US 20140154253A1 · Ng et al. · 2014 [cited by applicant]
US 20140288275A1 · Moore et al. · 2014 [cited by applicant]
US 20140302035A1 · Harms et al. · 2014 [cited by applicant]
US 20140302037A1 · Borges et al. · 2014 [cited by applicant]
US 20140308285A1 · Yan et al. · 2014 [cited by applicant]
US 20150376287A1 · Vu et al. · 2015 [cited by applicant]
US 20160122436A1 · Kufer et al. · 2016 [cited by applicant]
US 20160152707A1 · Kufer et al. · 2016 [cited by applicant]
US 20160257748A1 · Michaels et al. · 2016 [cited by applicant]
US 20170029502A1 · Raum et al. · 2017 [cited by applicant]
US 20170037149A1 · Raum et al. · 2017 [cited by applicant]
US 20170165373A1 · Armitage et al. · 2017 [cited by applicant]
US 20170218078A1 · Raum et al. · 2017 [cited by applicant]
US 20170349668A1 · Rattel et al. · 2017 [cited by applicant]
US 20180142021A1 · Weiss et al. · 2018 [cited by applicant]
US 20190151448A1 · Abel et al. · 2019 [cited by applicant]
US 20190169310A1 · Kufer et al. · 2019 [cited by applicant]
US 20190263920A1 · Vu et al. · 2019 [cited by applicant]
US 20200048357A1 · Raum et al. · 2020 [cited by applicant]
US 20200095319A1 · Kufer et al. · 2020 [cited by applicant]
US 20220251243A1 · Kufer et al. · 2022 [cited by applicant]
US 20220356268A1 · Kufer et al. · 2022 [cited by applicant]
US 20230357444A1 · Kufer et al. · 2023 [cited by applicant]
EP 0133988A2 · 1985 [cited by applicant]
EP 0171496A2 · 1986 [cited by applicant]
EP 0173494A2 · 1986 [cited by applicant]
EP 0239400A2 · 1987 [cited by applicant]
EP 0244234A2 · 1987 [cited by applicant]
EP 0402226A1 · 1990 [cited by applicant]
EP 0773288A2 · 1997 [cited by applicant]
EP 0843961A1 · 1998 [cited by applicant]
EP 1223964B1 · 2007 [cited by applicant]
EP 1806143A2 · 2007 [cited by applicant]
EP 2520590A2 · 2012 [cited by applicant]
EP 2762497A1 · 2014 [cited by applicant]
EP 2780375B1 · 2019 [cited by applicant]
GB 2177096A · 1987 [cited by applicant]
WO WO1987005330A1 · 1987 [cited by applicant]
WO WO1991006319A1 · 1991 [cited by applicant]
WO WO1992015673A1 · 1992 [cited by applicant]
WO WO1992022645A1 · 1992 [cited by applicant]
WO WO1992022647A1 · 1992 [cited by applicant]
WO WO1992022670A1 · 1992 [cited by applicant]
WO WO1996034096A1 · 1996 [cited by applicant]
WO WO1999001556A2 · 1999 [cited by applicant]
WO WO1999066951A2 · 1999 [cited by applicant]
WO WO2000006605A2 · 2000 [cited by applicant]
WO WO2000034317A2 · 2000 [cited by applicant]
WO WO2000040716A2 · 2000 [cited by applicant]
WO WO2000041474A2 · 2000 [cited by applicant]
WO WO2001012812A2 · 2001 [cited by applicant]
WO WO2001024811A1 · 2001 [cited by applicant]
WO WO2001087977A2 · 2001 [cited by applicant]
WO WO2002053596A2 · 2002 [cited by applicant]
WO WO2002066516A2 · 2002 [cited by applicant]
WO WO2003040170A2 · 2003 [cited by applicant]
WO WO2003047336A2 · 2003 [cited by applicant]
WO WO2003087131A2 · 2003 [cited by applicant]
WO WO2004106381A1 · 2004 [cited by applicant]
WO WO2004106383A1 · 2004 [cited by applicant]
WO WO2005040220A1 · 2005 [cited by applicant]
WO WO2005056606A2 · 2005 [cited by applicant]
WO WO2005061547A2 · 2005 [cited by applicant]
WO WO2005075511A1 · 2005 [cited by applicant]
WO WO2005118635A2 · 2005 [cited by applicant]
WO WO2006031370A2 · 2006 [cited by applicant]
WO WO2006138181A2 · 2006 [cited by applicant]
WO WO2007009064A2 · 2007 [cited by applicant]
WO WO2007033230A1 · 2007 [cited by applicant]
WO WO2007042261A2 · 2007 [cited by applicant]
WO WO2007097812A2 · 2007 [cited by applicant]
WO WO2007146968A2 · 2007 [cited by applicant]
WO WO2008119565A2 · 2008 [cited by applicant]
WO WO2008119566A2 · 2008 [cited by applicant]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2009132058A2 · 2009 [cited by applicant]
WO WO2010037835A2 · 2010 [cited by applicant]
WO WO2010037836A2 · 2010 [cited by applicant]
WO WO2010037837A2 · 2010 [cited by applicant]
WO WO2010037838A2 · 2010 [cited by applicant]
WO WO2010060486A1 · 2010 [cited by applicant]
WO WO2010104949A2 · 2010 [cited by applicant]
WO WO2012066058A1 · 2012 [cited by applicant]
WO WO2012163805A1 · 2012 [cited by applicant]
WO WO2013072406A1 · 2013 [cited by applicant]
WO WO2013072415A1 · 2013 [cited by applicant]
WO WO2014047231A1 · 2014 [cited by applicant]
WO WO2014089335A2 · 2014 [cited by applicant]
WO WO2012088461A2 · 2014 [cited by applicant]
WO WO2014122143A1 · 2014 [cited by applicant]
WO WO2014138449A1 · 2014 [cited by applicant]
WO WO2017134134A1 · 2017 [cited by applicant]
Lloyd et al., Protein Engineering, Design & Selection 22:159-168 (Year: 2009). [cited by examiner]
Edwards et al., J Mol Biol. Nov. 14, 2003;334(1): 103-118 (Year: 2003). [cited by examiner]
Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522-527 (Year: 2008). [cited by examiner]
Witte et al., Cancer and Metastasis Reviews 17: 155-161 (Year: 1998). [cited by examiner]
Alibaud et al., “A new monoclonal anti-CD3epsilon antibody reactive on paraffin sections”. J Histochem Cytochem. Dec. 2000;48(12):1609-1612. [cited by applicant]
Arnett et al., “Crystal structure of a human CD3-ε/δ dimer in complex with a UCHT1 single-chain antibody fragment”. PNAS Nov. 16, 2004;101(46):16268-16273. [cited by applicant]
Bello et al., “Loss of N-terminal charged residues of mouse CD3ε chains generates isoforms modulating antigen T cell receptor-mediated signals and T cell receptor-CD3 interactions”. J Biol Chem. Aug. 3, 2007;282(31):223… [cited by applicant]
Berkhoutt et al., “Transfection of genes encoding the T cell receptor-associated CD3 complex into COS cells results in assembly of the macromolecular structure”. J Biol Chem. Jun. 15, 1988;263(17):8528-8536. [cited by applicant]
Blumberg et al., “Structure of the T-cell antigen receptor: Evidence for two CD3ε subunits in the T-cell receptor-CD3 complex”. PNAS U.S.A. Sep. 1990;87(18):7220-7224. [cited by applicant]
Bortoletto et al., “Optimizing anti-DC3 affinity for effective T cell targeting against tumor cells”. Eur J Immunol. Nov. 2002;32(11):3102-3107. [cited by applicant]
Hansen et al., “Treatment of CD30-positive diseases, such as Hodgkin's lymphoma, by administration of a combination of sheddase inhibitor and anti-CD30 immunotherapeutic agents: Incyte Corporation: WO2007143600”. Exp Op… [cited by applicant]
Müller et al., “Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin”, J Biol Chem 2007, vol. 282, Issue 17, pp. 12650-12660. [cited by applicant]
Ridgway et al., “Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization”, Protein Eng. 1996, vol. 9, Issue 7, pp. 617-621. [cited by applicant]
Rogers et al., “Identification and characterization of macaque CD89 (immunoglobulin A Fc receptor)”. Immunol. Oct. 2004;113(2): 178-186. [cited by applicant]
Rossi et al., “Differential antibody binding to the surface αβTCR-CD3 complex of CD4 [cited by applicant]
Scheuermann et al., “CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy”. [Abstract] Leuk Lymphoma. Jan. 1, 1995;18(15): 385-397. [cited by applicant]
Schlereth et al., “Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct”. Cancer Res. Apr. 1, 2… [cited by applicant]
Sun et al., “Solution structure of the CD3εδ ectodomain and comparison with CD3εγ as a basis for modeling T cell receptor topology and signaling”. PNAS U.S.A., Nov. 30, 2004;101(48): 16867-16872. [cited by applicant]
U.S. Office Action dated Sep. 1, 2022 in related U.S. Appl. No. 17/336,152 in 36 pages. [cited by applicant]
U.S. Office Action dated Jan. 20, 2023 in related U.S. Appl. No. 17/336,152 in 35 pages. [cited by applicant]
U.S. Office Action dated Jun. 15, 2022 in related U.S. Appl. No. 17/672,546 in 36 pages. [cited by applicant]
EP Letter by Opposer James Poole Limited [O6] with Citations 119 & 120 [Experimental Report 1 & 2] filed Jun. 27, 2022 against EP 2780375, 16 pages. [cited by applicant]
EPO Preliminary Opinion for Opposers O1-O8 dated Sep. 21, 2022 in EP2780375, granted Sep. 11, 2019, 50 pages. [cited by applicant]
EPO Consolidated List of Opposition Documents dated Sep. 22, 2022 in EP 2780375, granted Sep. 11, 2019, 8 pages. [cited by applicant]
EPO Preliminary Opinion for Opposers O1-O7 dated Sep. 21, 2022 in EP2780374, granted Aug. 21, 2019, 77 pages. [cited by applicant]
EPO Consolidated List of Opposition Documents dated Sep. 27, 2022 in EP 2780374, granted Aug. 21, 2019, 6 pages. [cited by applicant]
Baeuerle et al., “BITE: a new class of antibodies t 1at recruit T-cells”, Drugs Future, 2008, vol. 33, Issue 2, pp. 1-11. [cited by applicant]
Baeuerle et al., “BITE Teaching antibodies to engage T-cells for cancer therapy”, Curr Opin Mol Thera, 2009, vol. 11, pp. 22-30. [cited by applicant]
Baeuerle et al., “Bispecific T-Cell Engaging Antibodies for Cancer Therapy”, Cancer Res, 2009, vol. 69, No. 12, pp. 4941-4944. [cited by applicant]
Bargou et al., “Tumor Regression in Cancer Patients by Very Low Doses of a T Ceil-Engaging Antibody”, Science, 2008, vol. 321, pp. 974-976. [cited by applicant]
Bellucci et al., “Complete Response to Donor Lymphocyte Infusion in Patients with Multiple Myeloma is Associated with Antibody Response to BCMA, a Plasma Celi Membrane Receptor”, Blood, 2003, vol. 102; pp. 192a-193a, Ab… [cited by applicant]
Bellucci et al., “Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens”, Blood, 2004, vol. 103, No. 2, pp. 656-663. [cited by applicant]
Bellucci et al., “Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor”, Blood, 2005, vol. 105, No. 10, pp. 3945-3950. [cited by applicant]
Betts et al., “Amino Acid Properties and Consequences of Substitutions”, Bioinformatics for Geneticists, 2003, Chapter 14, pp. 289-316. [cited by applicant]
Bio-Techne, “Human BCMA-TNFRSF17 antibody—technical sheet”, MAB193, bio-techne (R&D Systems), Aug. 15, 2016, 1 page. [cited by applicant]
Bodmer et al., “The molecular architecture of the TNF superfamily”, TRENDS Biochem Scien. Jan. 1, 2002;27(1): 19-26. [cited by applicant]
Bossen et al., “BAFF, APRIL and their receptors: Structure, function and signaling”, Seminars in Immunology, (2006) vol. 18, pp. 263-275. [cited by applicant]
Casset et al., “A Peptide Mimetic of an Anti-CD4 Monoclonal Antibody by Rational Design,” Biochemical and Biophysical Research Communications, 2003, vol. 307, pp. 198-205. [cited by applicant]
Chames et al., “Bispecific antibodies for cancer therapy—The light at the end of the tunnel?” MAbs, Nov. 1, 2009;6: 539-547. [cited by applicant]
Chames et al., “Bispecific antibodies for cancer therapy”, Curr Opin Drug Disc Devel., 2009, vol. 12, No. 2, pp. 276-283. [cited by applicant]
Chen et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity Matured Fab in Complex with Antigen,” J. Mol. Biol., 1999, vol. 293, pp. 865-881. [cited by applicant]
Choi et al., “Bispecific antibodies engage T cells for antitumor immunotherapy”, Expert Opin Bio Ther., Jul. 1, 2011;11(7): 843-853. [cited by applicant]
Clayton et al., “CD3η and CD3ζ are alternatively spliced products of a common genetic locus and are transcriptionally and/or post-transcriptionally regulated during T-cell development”, PNAS. Jun. 15, 1991;88(12): 5202-… [cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” Res Immunol., (1994) vol. 145, pp. 33-36. [cited by applicant]
Declaration of Dr. Rui Zhu, Jun. 9, 2020, 34 pages. [cited by applicant]
Declaration Natllan D. Trinklein, Ph.D., Jun. 8, 2020, 22 pages. [cited by applicant]
Declaration of Kevin C. Lindquist [O3] filed Jun. 9, 2020 with Annex 1 & 2 and Curriculum Vitae in 25 pages. [cited by applicant]
De Pascalis et al., “Grafting of ‘Abbreviated’ Complementarity Determining Regions Containing Specificity Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” … [cited by applicant]
Dillon et al., “An APRIL to remember: novel TNF ligands as therapeutic targets”, Nature Rev Drug Disc. Mar. 2006;5(3): 235-246. [cited by applicant]
Fitzgerald et al., “Gene structure”, The Cytokine FactsBook, Academic Press, 2nd Edition, 2001, pp. 151-152, in 5 pages. [cited by applicant]
Frank, A., [cited by applicant]
GenBank accession No. NM _000733, [cited by applicant]
GENBANK—Accession No. AB052772.1, “ [cited by applicant]
Guy et al., “Organization of proximal signal initiation at the TCR: CD3 complex”, Immunol Rev. Nov. 2009;232(1): 7-21. [cited by applicant]
Hager-Braun et al., “Determination of protein-derived epitopes by mass spectrometry”, Exp Rev Proteomics. Oct. 1, 2005;2(5): 745-756. [cited by applicant]
Hipp et al., “A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo”, Leukemia, Aug. 2017;31(8): 1743-1751. [cited by applicant]
Hönemann et al., “A novel recombinant bispecific single-chain antibody, bscWue-1 x CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells”, Leukemia. Mar. 2004;18(3): 636-644. [cited by applicant]
Huang et al., “Mapping binding epitopes of monoclonal antibodies targeting major histocompatibility complex class | c 1ain-reiated A (MICA) with hydrogen/deuterium exchange and electron-transfer dissociation mass spectr… [cited by applicant]
Hymowitz, S.G., et al., “Structures of APRIL-Receptor Complexes”, J Biol Chem., 2005, vol. 280, pp. 7218-7227. [cited by applicant]
Ito, W. et al., “The His-probe method: effects of histidine residues introduced into the complementary-determining regions of antibodies on antigen-antibody interactions at different pH values”, FEBS, Aug. 1992, vol. 30… [cited by applicant]
Kellner et al., “Effector Cell Recruitment by Bispecific Antibodies”, in [cited by applicant]
Kjer-Nielsen, L. et al., “Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the therapeutic mAb OKT3”, PNAS, May 2004, vol. 101, Issue 20, pp. 7675-7680. [cited by applicant]
Koarada et al., “Autoantibody-producing RP105 [cited by applicant]
Kontermann R.E., “Recombinant bispecific antibodies for cancer therapy”, Acta Pharmacol Sinica, (2005) 26(1): 1-9. [cited by applicant]
Kontermann R.E., “Bispecific Antibodies: Developments and Current Perspectives”, in Bispecific Antibodies, Springer, Berlin/Heidelberg 2011, Chapter 1, 2, 7, 11, 13, 14 and 15, in 152 pages. [cited by applicant]
Kufer, “A revival of bispecific antibodies”, Trends in Biotechnology, 2004, vol. 22, Issue 5, pp. 238-244. [cited by applicant]
Kuhns et al., “Deconstructing the form and function of the TCR/CD3 complex” Immunity, Feb. 1, 2006;24(2): 133-139. [cited by applicant]
Lamminmaki et al., “Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol,” The Journal of Biological Chemistry, vol. 276 (39), Sep. 28, 2001, pp. 36687-36694. [cited by applicant]
Leiba et al., “Activation of B-cell maturation antigen (BCMA)on human multiple myeloma cells by proliferation-inducing ligand (APRIL) promotes myeloma cell function in the bone marrow microenvironment”. Blood, Nov. 16, … [cited by applicant]
Li et al., “Mapping the energetic epitope of an antibody/interleukin-23 interaction with hydrogen/deuterium exchange, fast photochemical oxidation of proteins mass spectrometry, and alanine shave mutagenesis”. Anal Chem… [cited by applicant]
Liu, Y., et al., “Ligand-receptor binding revealed by the TNF family member TALL-1.”, Nature, 2003, vol. 423, Issue 6935, pp. 49-56. [cited by applicant]
Löfblom et al., “Alternative scaffolds as bispecific antibody mimetics”, in [cited by applicant]
MacCallum et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J Mol Biol., 1996, vol. 262, pp. 732-745. [cited by applicant]
Moreaux et al., “APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop”, European J Haematol., 2009, vol. 83, Issue 2, pp. 119-129. [cited by applicant]
Müller et al., “Recombinant Bispecific Antibodies for Cancer Therapy”, in [cited by applicant]
Müller et al., “Recombinant bispecific antibodies for cellular cancer immunotherapy”, Curr Opin Mol Thera. Aug. 1, 2006;9(4): 319-326. [cited by applicant]
NCBI Reference Sequence NP 001183 (Apr. 26, 2014). [cited by applicant]
Neisig et al., “Assembly of the T-cell antigen receptor. Participation of the CD3 omega chain”, J Immunol. Jul. 15, 1993;151(2): 870-879. [cited by applicant]
Novak et al., “Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival”, Blood, 2004, vol. 103, pp. 689-694. [cited by applicant]
Padlan et al., “Structure of an Antibody-Antigen Complex: Crystal Structure of the HyHEL 10 Fab-Lysozyme Complex,” PNAS U.S.A. Aug. 1989;86: 5938-5942. [cited by applicant]
Panowski et al., “Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma”, Molecular Cancer Therapeutics, 2019, vol. 18, No. 11, pp. 2008-202… [cited by applicant]
Patel et al., “Engineering an APRIL-specific B cell maturation antigen”, J Biol Chem. Apr. 16, 2004;279(16): 16727-16735. [cited by applicant]
Pelekanou et al., “Expression of TNF-superfamily members BAFF and APRIL in breast cancer: . . . ” BMC Cancer, 2008, vol. 8, No. 76, pp. 1-9. [cited by applicant]
Puchades et al., “Epitope mapping of diverse influenza Hemagglutinin drug candidates using HDX-MS”, Sci Rep., 2019, vol. 9, Issue 1, 4735 in 10 pages. [cited by applicant]
Ramadoss, et al., “An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma,” J Am Chem Soc., Apr. 29, 2015;137(16): 5288-5291. [cited by applicant]
Rennert et al., “A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth.” J Exp Med., 2000, vol. 192, Issue 11, pp. 1677-1683. [cited by applicant]
Rudikoff et al. “Single Amino Acid Substitution Altering Antigen Binding Specificity”, Proc. Natl. Acad. Sci., Mar. 1, 1982;79(6): 1979-1983. [cited by applicant]
Ryan, M.C., et al., “Antibody targeting of B-cell maturation antigen on malignant plasma cells”, Mol Cancer Ther, 2007, vol. 6, Issue 11, pp. 3009-3018. [cited by applicant]
Santa Cruz Biotechnology, Inc., “BCMA (Vicky-1): sc-57037—Product Data Sheet”, (Aug. 13, 2009) URL: http://datasheets.scbt.com/sc-57037.pdf; XP055720861; 1 page. [cited by applicant]
Sequence alignment of BCMA extracellular domain; human, rhesus macaque, 1 page. [cited by applicant]
Sequence alignment of CD3 epsilon N-term aa1-27; human, crab eating macaque, rhesus macaque, 1 page. [cited by applicant]
Sequence alignment of CD3 epsilon; crab-eating macaque, rhesus macaque , 1 page. [cited by applicant]
Tarte et al., “BAFF is a Survival Factor for Multiple Myeloma Cells”, Myeloma Biology II, Abstract #3203/623-III, p. 811a, 2002. [cited by applicant]
Thakur et al., “Cancer therapy with bispecific antibodies: Clinical experience.” Curr Opin Mol Ther., Jun. 2010;12(3) 340-349. [cited by applicant]
UNIPROT “Tumor necrosis factor receptor superfamily member 17”, Q02223—TNR17, Jul. 27, 2011, 8 pages. [cited by applicant]
Vajdos et al., “Comprehensive Functional Maps of the Antigen Binding Site of an Anti ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol., 2002, vol. 320, pp. 415-428. [cited by applicant]
Vidal-Laliena et al., “Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry”, Cellular immunol., 2005, vo… [cited by applicant]
Wallweber et al., “The crystal structure of a proliferation—inducing ligand, APRIL.”, J Mol Biol., Oct. 15, 2004;343(2): 283-290. [cited by applicant]
Walters et al., “Minimizing back exchange in the hydrogen exchange—mass spectrometry experiment.” J Am Soc Mass Spectrom., 2012, vol. 23, No. 12, pp. 2132-2139. [cited by applicant]
Wu et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J. Mol. Biol., 1999, vol. 294, pp. 151-162. [cited by applicant]
Yu et al., “Interaction between Bevacizumab and Murine VEGF-A: A Reassessment”, Investigative Ophthalmology & Visual Science, 2008, vol. 49, pp. 522-527. [cited by applicant]
Zhang et al., “Epitope mapping of a 95 kDa antigen in complex with antibody by solution—phase amide backbone H/D exchange monitored by Fourier transform ion cyclotron resonance mass spectrometry”, Anal Chem., 2011, vol.… [cited by applicant]
Zhang et al., “Epitope Mapping by HDX-MS Elucidates the Surface Coverage of Antigens Associated with High Blocking Efficiency of Antibodies to Birch Polen Allergen”, Anal Chem., 2018, vol. 90, Issue 19, 11315-11323. [cited by applicant]
Zhang et al., Analytical Chemistry, Oc01291, pp. 1-18, 2020. [cited by applicant]
International Search Report and Written Opinion and International Search Report for International Application No. PCT/EP2012/072699; mailed on Mar. 27, 2013 in 14 pages. (WO 2013/072406). [cited by applicant]
Altschul et al., “Basic local alignment tool”. J Mol Biol. (1990) 215: 403-410. [cited by applicant]
Altschul S., “Local alignment statistics”. Meth Enzymol. (1996) 266: 460-480. [cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: A new generation of protein database search programs”. Nucl Acids Res. (1997) 25(17): 3389-3402. [cited by applicant]
AMGEN—In-house data showing the KD of E1/E4-BCMA/CD3 Bispecific Antibodies and E3-BCMA/CD3 Bispecific Antibodies, 1 page, Feb. 1, 2021. [cited by applicant]
Angeletti R., “Design of useful peptide antigens”, J Biomol Tech., 1999, vol. 10, Issue 1, pp. 2-10. [cited by applicant]
Ansell et al., “Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma”, J Clin Oncol., 2007, vol. 25, Issue 19, pp. 2764-2769. [cited by applicant]
Aplin et al., “Preparation, properties, and applications of carbohydrate conjugates of proteins and lipids”. CRC Critic Rev Biochem. Jan. 1, 1981; 10(4): 259-306. (1981 ). [cited by applicant]
Artsaenko et al., “The expression of a single-chain Fv antibody against abscisic acid creates a wilty phenotype in transaenic tobacco”. The Plant J. Nov. 1995; 8(5): 745-750. [cited by applicant]
Asano et al., “Humanization of the bispecific epidermal grown factor receptor [cited by applicant]
Bird et al., “Single-chain antigen-binding proteins”. Science Oct. 21, 1988;242(4877): 423-426. [cited by applicant]
Bluemel et al., “Epitope Distance to the Target Cell Membrane and Antigen Size Determine the Potency of T Cell-mediated Lysis by BiTE Antibodies Specific for a Large Melanoma Surface Antigen”, Cancer Immunol Immunother.… [cited by applicant]
Bork P., “Powers and pitfalls in sequence analysis: The 70% hurdle”. Genome Res. Apr. 1, 2000;10(4): 398-400. [cited by applicant]
Bork et al., “Go hunting in sequence databases but watch out for the traps”. Trends Gen. Oct. 1, 1996;12(10): 425-427. [cited by applicant]
Brinkmann et al., “The making of bispecific antibodies”, Mabs., Feb. 17, 2017;9(2): 182-212. [cited by applicant]
Brenner S.E., “Errors in genome function”. Trends Genet. Apr. 1999;15(4): 132-133. [cited by applicant]
Brok et al., “An extensive monoclonal antibody panel for the phenotyping of leukocyte subsets in the common marmoset and the cotten-top tamarin”. Cytometry, (2001) 45: 294-303. [cited by applicant]
Brühl et al., “Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: A new strategy in the treatment of chronic inflammatory diseases and HIV”. Immunol. Feb. 15, 2001;166(4): 2420-2426. [cited by applicant]
Brummell et al., “Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residuesBiochem”. Feb. 2, 1993;32(4): 1180-1187. [cited by applicant]
Burks et al., “In vitro scanning saturation mutagenesis of an antibody binding pocket”. PNAS. Jan. 21, 1997;94(2): 412-417. [cited by applicant]
Caldas et al., “Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen”, Mol Immunol. 2003, vol. 39, pp. 941-952. [cited by applicant]
Carpenter et al., “B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma”. Clin Cancer Res. Apr. 15, 2013;19(8): 2048-2060. [cited by applicant]
Carter et al., “Humanization of an anti-p185 [cited by applicant]
Carter et al., “High level [cited by applicant]
Carter et al., “Potent antibody therapeutics by design”. Nat Rev Immunol. (2006) 6: 343-357. [cited by applicant]
Chalfie et al., “Green fluorescent protein as a marker for gene expression”. Science Feb. 11, 1994;263(5148): 802-805. [cited by applicant]
Chen et al., “Enhancement and Destruction of Antibody Function by Somatic Mutation: Unequal Occurrence is Controlled by V Gene Combinatorial Associations”, The EMBO Journal, vol. 14, No. 12, 1995, pp. 2784-2794. [cited by applicant]
Chien et al.,“Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism”, Proc. Natl. Acad. Sci. USA, Jul. 1989, vol. 86, pp. 5532-5… [cited by applicant]
Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins”. J Mol Biol. Aug. 20, 1987;196(4): 901-917. [cited by applicant]
Chothia et al., “Conformation of immunoglobulin hypervariable regions”. Nature Dec. 21, 1989; 342(6252): 877-883. [cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries”. Letts Nature Aug. 1991;352(6336): 624-628. [cited by applicant]
Cochran et al., “Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments”, Journal of Immunological Methods, 2004, vol. 287, pp. 147-158. [cited by applicant]
Conrad et al., “TCR and CD3 antibody cross-reactivity in 44 species”. J Int Soc Anal Cytol. Nov. 2007;71(11): 925-933. [cited by applicant]
Cook et al., “The human immunoglobulin VH repertoire”. Immunol Today Jan. 1, 1995; 16(5): 237-242. [cited by applicant]
Coquery et al., “Regulatory roles of the tumor necrosis factor receptor BCMA”. Crit Rev Immunol. (2012) 32(4): 287-305. [cited by applicant]
Criado et al., “Variability of invariant mouse CD3epsilon chains detected by anti-CD3 antibodies”, Eur J Immunol., 2000, vol. 30, Issue 5, pp. 1469-1479. [cited by applicant]
Da Costa et al., “Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease”, Cancer Chemo Pharmacol., Springer Verlag, Berlin, 2000, vol. 46, No. Suppl, pp. S35-S36. [cited by applicant]
Declaration—Dr. Robert Saller, Amgen Research Executive Director, Jan. 2, 2010, 1 page. [cited by applicant]